30 closest matches · ranked by relevance
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Primary Mediastinal B-cell Lymphoma · Diffuse, Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants
Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count >= 500/Mcl for 3 Consecutive Measurements on Different Days and Platelet Count > 20,000/mm^3 With no Platelet…
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Hairy Cell Leukemia
Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants
Leukemia · Lymphoma · Multiple Myeloma and Plasma Cell Neoplasm
Primary: Complete Remission Rate — 8; 6 Participants
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Lymphoma · Leukemia
Primary: Composite Success Rate — 100; 75; 84 Percentage of participants
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Leukemia · Lymphoma
Primary: Number of Transplant Recipients With Successful Engraftment — 70 Participants
Lymphoma, Non-Hodgkin
Primary: Progression-Free Survival (PFS) — 73 percentage of participants
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
T Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate — 0.0 proportion of participants
Refractory B-Lineage Leukemia · Relapsed B-Lineage Leukemia · Refractory B-Lineage Lymphoma
Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Peripheral T Cell Lymphoma
Primary: Overall Response Rate (ORR) at Four Months (LYRIC Criteria) — 2; 0; 1 Participants
Hematological Malignancies
Primary: Overall Survival at 6 Months Post-transplant in Patients Receiving a Partially-matched Related Donor Allogeneic Transplant After Reduced-intensity Conditioning — 22…
Leukemia · Lymphoma
Primary: Survival at 1 Year After Transplantation — 10; 6 participants
Lymphoma · T-Cell · Cutaneous
Primary: Response Rate — 0; 0; 1; 1 Participants
Lymphomatoid Granulomatosis · Granulomatosis, Lymphomatoid · Non-Hodgkins Lymphoma
Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants
Acute Myeloid Leukemia · Acute Lymphocytic Leukemia · Myelodysplasia
Primary: One-year Survival — 50 percentage of participants
Hematologic Neoplasms
Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Recurrent Adult Acute Lymphoblastic Leukemia · Recurrent Adult Acute Myeloid Leukemia
Primary: Safety of DLI Following a Non-myeloablative Transplant, Defined as Incidence of Grade IV Acute GVHD — 5.7 percentage of participants
Hodgkin's Disease
Primary: Transplant Related Mortality Rate — 1; 6 Participants
Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Summary of Adverse Events (AEs) — 9; 13; 7; 12 participants
T-LGL Lymphoproliferative Disorders
Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants